Sex differences in nevirapine rash

Area of Science:

• Pharmacology
• Clinical Medicine
• HIV/AIDS Research

Background:

• Nevirapine is a common nonnucleoside reverse transcriptase inhibitor (NNRTI) used in HIV treatment.
• Rash is a frequent side effect, potentially limiting treatment adherence.
• Previous studies indicated a higher incidence of severe rash in men, but further investigation into sex-based differences is warranted.

Purpose of the Study:

• To investigate the association between sex and the risk of severe rash and treatment discontinuation in patients receiving nevirapine.
• To quantify the risk of severe rash and its impact on therapy adherence in women compared to men.

Main Methods:

• A multicenter, retrospective cohort study was conducted over a 5-year period.
• Data from patients receiving nevirapine were analyzed to compare the incidence of severe rash and discontinuation rates between sexes.
• Multivariate analysis was used to adjust for age and baseline CD4 cell count.

Main Results:

• Women experienced a significantly higher risk of severe rash (Risk Ratio [RR], 8.31) and were more likely to discontinue nevirapine due to rash (RR, 4.5).
• After adjusting for covariates, women had a 7-fold increased risk for severe rash and were 3.5 times more likely to discontinue therapy.
• The P-values for these associations were statistically significant (P=.005 for rash, P=.0005 for discontinuation).

Conclusions:

• Significant sex differences exist in the occurrence and management of nevirapine-associated severe rash.
• Women face a substantially higher risk of severe rash and subsequent treatment discontinuation.
• Awareness of these disparities is essential for informed nevirapine prescription, particularly in women of reproductive age.